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not adequately controlled (NAC), not seizure free (NSF), seizure free (SF) and death. 
The length of each Markov cycle is 1 year for the whole study period. Patients could 
stay in the NAC state, move to the NSF or SF state, or die, according to the respective 
efficacy of each treatment. Utility values associated with each health state were 
used to estimate the number of QALYs associated with each treatment. Analyses 
were conducted from both a Canadian Ministry of Health (MoH) and a societal 
perspective. Results: Compared with VPA+CLB, STP+VPA+CLB was associated 
with incremental cost-effectiveness ratios of CAD$50,122/QALY from a MoH per-
spective and was dominant from a societal perspective. Results of the probabilistic 
sensitivity analysis indicated that the ICUR remained below CAD$100,000 in 98.4% 
and in 100% of the simulations from a MoH and a societal perspective respec-
tively. ConClusions: This economic evaluation demonstrates that STP+VPA+CLB 
is a cost-effective strategy as adjunctive therapy in patients with SMEI whose sei-
zures are not adequately controlled with VPA+CLB alone.
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objeCtives: Atypical hemolytic uremic syndrome (aHUS) is a rare genetic disease 
affecting kidney function that predominantly affects children. The objective of this 
study was to evaluate hospital-based utilization in patients with aHUS. Methods: 
A retrospective cross-sectional study was conducted on 6571 aHUS discharges in 
the MedAssets health system data for inpatient (IP) and outpatient (OP) visits for 
the January 2009 to December 2013 timeframe. Age and gender, hospital charac-
teristics, clinical comorbidities and measures of utilization including number of 
visits and length of stay (LOS) were described. Multivariable regression was used 
to identify significant drivers of hospital-based utilization. Results: The sample 
included 2089 patients with more than 76.0% of the hospital visits occurring in 
the outpatient setting. The mean age of the sample was 23 years with 59.3% under 
the age of 18 and 61.0% female. More than 60% of the visits occurred in teaching 
facilities and facilities with 300 beds or more. Among inpatient admissions, the 
average LOS was 16.02 days with the most common procedures being packed 
cell transfusions (41.7%) therapeutic plasmapheresis (29.8%) and serum transfu-
sion (17.4%). Same-hospital readmissions occurred in 14.5% of the inpatient sam-
ple. Comorbidities for this population included renal disease (56.2%), congestive 
heart failure (11.1%), chronic pulmonary disease (10.0%) and diabetes without 
chronic complications (8.0%). Cardiovascular disease (2.8 days, p< .001), rheumatic 
disease (2.5 days, p< .05), and malignancy (4.2 days, p< .0001) were significantly 
associated with longer inpatient LOS. ConClusions: Patients with aHUS con-
sume a significant amount of health care resources. Further research is required 
to understand the effect of interventions/treatments on mitigating the progress 
of this disease.
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objeCtives: As of December 2013, there were over 20 drugs available in the US for 
the treatment of POS. The aim of this study is to understand the remaining burden of 
disease and the need for newer treatments. Methods: Data from the 2012 and 2013 
U.S. National Health and Wellness Survey (NHWS) was analyzed. The NHWS is self-
administered, internet-based survey of a nationwide sample of adults (18+ years) 
stratified to represent the demographic composition of the U.S. population. Patients 
self-reported a diagnosis of epilepsy with POS and were grouped as uncontrolled (> = 
1 seizure per month) and controlled (< 1 seizure per month). Patients provided infor-
mation on health status (mental (MCS), physical component summary (PCS), and 
SF-6D (health utility) scores from the SF-36v2), resource utilization in the past six 
months and treatment satisfaction with current epilepsy prescription medication (1 
[extremely dissatisfied] to 7 [extremely satisfied]). Regression modeling controlled 
for covariates. Results: Among 207 diagnosed epilepsy with POS patients, 38.6% 
were uncontrolled and 61.4% were controlled. Uncontrolled vs. controlled patients 
were similar in age, gender and ethnicity, but were more likely to be in a commit-
ted relationship, less educated, and employed (p< 0.05). Uncontrolled vs. controlled 
patients had lower health utilities (0.66 vs. 0.70, p= 0.015), MCS scores (43.05 vs. 47.10, 
p= 0.008), and non-significant PCS scores (47.95 vs. 49.12, p= 0.371). Uncontrolled vs. 
controlled patients reported more emergency room visits (207.7%, p= 0.002), hospi-
talizations (447.9%, p< 0.001), and traditional provider visits were non-significantly 
greater (22.8%, p= 0.197). Amongst treated patients, treatment satisfaction was lower 
for uncontrolled vs. controlled (5.27 vs. 5.86, p= 0.01). ConClusions: Despite the 
availability of existing anti-epileptic drugs (AED) in 2013, the results suggest a sig-
nificantly higher economic and humanistic burden in patients with uncontrolled 
seizures. POS patients are very much in need of additional treatment options for 
which newer AEDs may provide a solution.
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bACkgRound: MS is known to be a costly and intensive condition to treat which 
allows for an opportunity to better understand how non-clinical factors can impact 
costs and other economic measures. objeCtives: To observe and report variances 
respectively. Thus, delayed-release dimethyl fumarate was dominant (had lower 
costs and higher QALYs gained) compared to glatiramer acetate and fingolimod. 
Sensitivity analyses showed that delayed-release dimethyl fumarate was less 
costly and more effective than glatiramer acetate and fingolimod for most of the 
input parameter values and assumptions tested. ConClusions: Delayed-release 
dimethyl fumarate, a new oral drug indicated for RRMS, is a cost-effective treat-
ment when compared to glatiramer acetate and fingolimod. Sensitivity analyses 
support the robustness of the model results.
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objeCtives: Evaluate the cost effectiveness of Tetrabenazine for the treatment 
of chorea in Mexican patients with Huntington disease versus current therapy, 
from a governmental perspective. Methods: Cost-effectiveness and a cost utility 
analysis were done. Effectiveness measurements were: percentage of successful 
patients treated and QALYs. Disease-specific utility values assigned to each disease 
state, have been estimated by Mevhibe 2009 using instrument Huntington’s disease 
health-related quality of life questionnaire, and expert opinion. Costs considered are 
direct medical care, drug, adverse events. Analysis used a governmental perspective 
(Mexican Institute of Social Services costs). The model contains four arms, one for 
each alternative to compare: tetrabenazine, olanzapine, haloperidol and risperidone. 
A Markov model was performed considering 80 weeks horizon with 1 week cycles 
simulating Mexican population with the proposed treatment alternatives. Finally a 
univariated probabilistic sensitivity analysis was done to validate consistency in the 
model. Results: Tetrabenazine generated the lowest cost per patient ($3,728USD), 
followed by risperidone ($ 4,632USD), haloperidol ($4,790USD), the alternative that 
generates the largest cost is olanzapine ($4,954) (conversion rate: USD= 13.1 MxPesos. 
Average 2013). In terms of effectiveness, we find that tetrabenazine arm has the 
highest proportion of successful treatments regarding their comparators (56.0%, 
95% CI: 46.0 - 65.0%), as well as a greater number of QALYs gained (QALY 1.166, 95% 
CI: 1130-1203) ConClusions: The use of tetrabenazine itself can be considered a 
cost-effective from the perspective of dominant institutions of public health inter-
vention in Mexico, since it is a less expensive and more effective strategy regarding 
its comparators.
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objeCtives: Buccolam (licensed midazolam oromucosal solution) is indicated in 
prolonged, acute, convulsive seizures (PACS) in pediatric patients. Clinical data con-
firm that midazolam oromucosal solution is at least as effective as existing treat-
ments. Current-care in Italy for community PACS is rectal diazepam, which carers 
are often reluctant to use due to social acceptability issues. The aim of this study was 
to establish whether use of Buccolam could affect the cost of treatment. Methods: 
A decision-tree model was developed to perform cost-minimisation analysis com-
paring Buccolam and rectal diazepam for the treatment of PACS in children initially 
occurring in the community setting. The model captures the treatment pathway for 
children experiencing a PACS including whether treatment is administered in the 
community, whether an ambulance is required and whether the patient is hospi-
talised. Costs were taken from Farmadati Italia and official DRGs. Efficacy estimates 
were taken from published literature whereas, due to a lack of available evidence, 
effectiveness was estimated by a 4-round Delphi-panel process consisting of leading 
Italian clinicians. Results: Over one year, compared to rectal diazepam, Buccolam 
showed a reduction in per patient costs of € 1,765 from an INHS perspective. The 
largest saving came from an estimated reduction in inpatient costs: € 1,677 per 
patient per year. Estimates of budget impact over five years varied from a saving 
of € 76 million to over € 152 million when low and high-case population estimates 
were used. ConClusions: Treatment with Buccolam is estimated to be cost sav-
ing, through a reduction in the need for ambulance call-outs and hospital stays. 
Treatment with Buccolam is expected to increase the number of PACS resolved in 
the community through increased carer willingness to treat seizures and fewer 
failed deliveries: Buccolam has a more acceptable method of administration that 
avoids compromising patients’ dignity and an easier administration route com-
pared to diazepam.
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objeCtives: Severe myoclonic epilepsy in infancy (SMEI, Dravet Syndrome) is a 
severe type of pharmacoresistant epilepsy, characterized by repeated and prolonged 
generalized seizures. Patients with SMEI show important delays in psychomotor 
and cognitive development that often progress in eventual mental retardation. 
Stiripentol (STP) has been approved in Canada for use in conjunction with valproate 
(VPA) + clobazam (CLB) as adjunctive therapy in patients with SMEI whose seizures 
are not adequately controlled with VPA+CLB alone. The objective of this study was 
to assess, from a Canadian perspective, the economic impact of STP+VPA+CLB com-
pared with VPA+CLB in the treatment of SMEI. Methods: The cost-effectiveness of 
STP+VPA+CLB compared to VPA+CLB in the treatment of SMEI was assessed over 
a 5-year horizon using a Markov model. The model comprises four health states: 
